TP53 RB1 and PTEN alterations affect prognosis and ARPI response in metastatic hormone-sensitive prostate cancer, potential for treatment personalization based on both genomic testing and clinical ...

Zachary Klaassen hosts Andrew Hahn to discuss future directions in metastatic castration-resistant prostate cancer. Dr. Hahn highlights the "golden era" for targeting cell surface proteins through ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Bladder Cancer - Read the latest Bladder Cancer research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Mario Fernández, MD, Melanie Pepin, MS, CGC, and Kristen Watts The Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Think Tank 2025, was host to the Breakout Session: Tracking and Tackling an ...

PSMA and Beyond 2025 PSMAfore trial, SPLASH trial, ECLIPSE trial, PSMA radioligand therapy, PSMAfore compared to SPLASH, SPLASH LuPSMA arm, PSMAfore LuPSMA arm, ProstACT GLOBAL.

Erectile Dysfunction - Read the latest Erectile Dysfunction research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

Prostatitis - Read the latest Prostatitis research including Full-Text Abstracts as well as "Beyond the Abstract" articles, written by the researchers exclusively for UroToday.

ASCO 2025, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), CCTG IND 234 PC_BETS, Carboplatin, DDR alterations.

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial in progress (NCT04689828). This ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

ASCO 2025 fully automated PSMA PET quantification, overall survival in patients undergoing 177Lu PSMA therapy, PSMA SUVmean, metastatic castrate resistant prostate cancer (mCRPC).